Finding the best HIV treatment after PrEP shot failure
Part of Infections clinical trials.
This trial is for people who got exposed to HIV despite taking the long-acting PrEP shot (cabotegravir). It tests different pill-based HIV treatment plans to find the best option for them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HIV and have taken at least one dose of the injectable PrEP (cabotegravir) in the past year.
- You are willing to start HIV treatment with pills (antiretroviral therapy).
- You are 15 years or older and weigh at least 35 kg (about 77 lbs).
- Your kidney function (a simple blood test) must be above a certain level.
- You have not taken the HIV medicine dolutegravir (DTG) before.
- You are not currently taking TB medicines like rifampicin or certain seizure medications or St. John's Wort.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how taking two tablets of a PrEP medication (F/TAF) at once affects healthy volunteers. It helps us understand the safety and how the body processes the drug.
This trial checks how well PrEP pills (TDF/FTC) prevent HIV in people who are at high risk and are HIV-negative. It may help you understand whether PrEP is a good prevention option for your situation.
This study follows adults who are at high risk of getting HIV while they take HIV prevention pills (PrEP). It aims to learn how well PrEP fits real-life use in people at risk and who may need extra care.
This Phase 3 study tests whether an injectable HIV prevention medicine (cabotegravir) given before exposure can help prevent HIV in people at higher risk. You may join if you are HIV-negative and meet specific sexual health, medication, and health-testing requirements.
This trial tests a new HIV prevention medicine called lenacapavir, given as a shot every six months. It's for young people at risk of HIV who haven't used PrEP before or have had gaps in their PrEP use.
This trial looks at how well a daily HIV-prevention pill (F/TAF) works in people who use drugs. The goal is to understand real-world effectiveness and help support people in staying HIV-negative.
Hear when a new HIV Prevention trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.